# US 2024/0197758 A1 · Psilocybin compositions, methods of making and methods of using the same

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0197758 A1
- Document ID: US20240197758A1
- Status: Published application
- Kind: A1
- Application number: 18/285,109
- Filed: 2022-03-30
- Published: 2024-06-20
- Earliest claimed: 2021-03-30
- Assignees: Compass Pathfinder Limited
- Applicants: Compass Pathfinder Limited
- Inventors: David Philip ELDER; Nigel RICHARDSON
- Web page: https://patentgrep.com/patent/US20240197758A1

## CPC

- A61K 9/4858: {Organic compounds}
- A61K 31/661: Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion {or mevinphos}
- A61K 9/08: Solutions {(composition of solutions A61K47/00)}
- A61K 9/2013: {Organic compounds, e.g. phospholipids, fats}
- A61K 9/2059: {Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin}
- A61K 9/4833: {Encapsulating processes; Filling of capsules (mechanical aspects A61J3/07)}
- A61K 9/4866: {Organic macromolecular compounds}
- A61K 31/675: having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
- A61K 47/14: Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
- A61K 47/36: Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61P 25/24: Antidepressants
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present disclosure provides pharmaceutical compositions comprising a therapeutically effective amount of psilocybin and one or more pharmaceutically acceptable excipients. Methods of making such compositions and use thereof in treating depressive disorders are also disclosed.

## Claims

### Claim 1

A pharmaceutical composition comprising:
a therapeutically effective amount of psilocybin; and
one or more pharmaceutically acceptable excipients,
wherein, after storage of the composition at 40° C. and 75% relative humidity for one month, the potency of the psilocybin in the composition decreases by less than 5% and the mass balance of psilocybin and related substances is greater than 97%.

### Claim at position 2

2-38. (canceled)

### Claim 39

A method of making a pharmaceutical composition comprising:
a) direct mixing psilocybin and one or more pharmaceutically acceptable excipients to provide a blend, and
b) filling a capsule with the blend to provide the pharmaceutical composition,
wherein the content uniformity of the composition complies with the European Pharmacopeia 2.96. or USP <905>.

### Claim at position 4

40-52. (canceled)

### Claim 53

A pharmaceutical composition comprising:
a therapeutically effective amount of psilocybin; and
about 85% to about 99%, by weight, partially pregelatinized starch.

### Claim 54 (depends on 53)

The pharmaceutical composition of claim 53, further comprising a lubricant.

### Claim 55 (depends on 54)

The pharmaceutical composition of claim 54, wherein the composition comprises about 0.5% to about 2.0%, by weight, the lubricant.

### Claim 56 (depends on 55)

The pharmaceutical composition of claim 55, wherein the lubricant is sodium stearyl fumarate.

### Claim 57 (depends on 53)

The pharmaceutical composition of claim 53, wherein the composition is a capsule.

### Claim 58 (depends on 53)

The pharmaceutical composition of claim 53, wherein the composition comprises about 1% to about 10%, by weight, psilocybin.

### Claim 59 (depends on 53)

The pharmaceutical composition of claim 53, wherein the composition does not contain silicified microcrystalline cellulose.

### Claim 60 (depends on 53)

The pharmaceutical composition of claim 53, wherein the composition comprises 1 mg of psilocybin.

### Claim 61 (depends on 53)

The pharmaceutical composition of claim 53, wherein the composition comprises 5 mg of psilocybin.

### Claim 62 (depends on 53)

The pharmaceutical composition of claim 53, wherein the composition comprises 10 mg of psilocybin.

### Claim 63 (depends on 53)

The pharmaceutical composition of claim 53, wherein the composition comprises 25 mg of psilocybin.

### Claim 64 (depends on 53)

The pharmaceutical composition of claim 53, wherein the composition comprises 40 mg of psilocybin.

### Claim 65

A pharmaceutical composition comprising:
about 1% to about 10%, by weight, psilocybin;
about 85% to about 99%, by weight, partially pregelatinized starch; and
about 0.5% to about 2.0%, by weight, sodium stearyl fumarate.

### Claim 66 (depends on 65)

The pharmaceutical composition of claim 65, wherein the composition does not contain silicified microcrystalline cellulose.

### Claim 67 (depends on 65)

The pharmaceutical composition of claim 65, wherein the composition is a capsule.

### Claim 68 (depends on 65)

The pharmaceutical composition of claim 65, wherein the composition comprises 1 mg of psilocybin.

### Claim 69 (depends on 65)

The pharmaceutical composition of claim 65, wherein the composition comprises 5 mg of psilocybin.

### Claim 70 (depends on 65)

The pharmaceutical composition of claim 65, wherein the composition comprises 10 mg of psilocybin.

### Claim 71 (depends on 65)

The pharmaceutical composition of claim 65, wherein the composition comprises 25 mg of psilocybin.

### Claim 72 (depends on 65)

The pharmaceutical composition of claim 65, wherein the composition comprises 40 mg of psilocybin.
